Core One Labs Inc. (CLABF)
USD 0.04
(-10.28%)
USD 0.04
(-10.28%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 416.34 Thousand CAD | 5.98% |
| 2021 | 392.84 Thousand CAD | 0.0% |
| 2020 | - CAD | 100.0% |
| 2019 | -669.57 Thousand CAD | 60.37% |
| 2018 | -1.68 Million CAD | -983.96% |
| 2017 | 191.12 Thousand CAD | 240.77% |
| 2016 | 56.08 Thousand CAD | -1.08% |
| 2015 | 56.69 Thousand CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | -60.34 Thousand CAD | -124.09% |
| 2023 Q2 | 83.26 Thousand CAD | 237.98% |
| 2023 Q3 | 60.61 Thousand CAD | -27.21% |
| 2022 FY | 416.34 Thousand CAD | 5.98% |
| 2022 Q4 | 250.48 Thousand CAD | 145.86% |
| 2022 Q1 | 132.05 Thousand CAD | -69.4% |
| 2022 Q2 | 136.38 Thousand CAD | 3.28% |
| 2022 Q3 | 101.88 Thousand CAD | -25.3% |
| 2021 FY | 392.84 Thousand CAD | 0.0% |
| 2021 Q1 | - CAD | 100.0% |
| 2021 Q2 | - CAD | 0.0% |
| 2021 Q3 | - CAD | 0.0% |
| 2021 Q4 | 431.61 Thousand CAD | 0.0% |
| 2020 Q2 | 675.19 Thousand CAD | 1089.46% |
| 2020 Q3 | 901.34 Thousand CAD | 33.49% |
| 2020 Q4 | -2.25 Million CAD | -349.68% |
| 2020 FY | - CAD | 100.0% |
| 2020 Q1 | 56.76 Thousand CAD | 112.53% |
| 2019 Q2 | 493.72 Thousand CAD | 205.55% |
| 2019 FY | -669.57 Thousand CAD | 60.37% |
| 2019 Q4 | -452.96 Thousand CAD | -86.74% |
| 2019 Q1 | -467.77 Thousand CAD | 78.61% |
| 2019 Q3 | -242.56 Thousand CAD | -149.13% |
| 2018 Q4 | -2.18 Million CAD | -1303.16% |
| 2018 FY | -1.68 Million CAD | -983.96% |
| 2018 Q2 | 315.69 Thousand CAD | 0.0% |
| 2018 Q1 | - CAD | 100.0% |
| 2018 Q3 | 181.76 Thousand CAD | -42.42% |
| 2017 Q2 | 68.12 Thousand CAD | -61.6% |
| 2017 Q1 | 177.38 Thousand CAD | 436.99% |
| 2017 Q4 | -628.13 Thousand CAD | 0.0% |
| 2017 FY | 191.12 Thousand CAD | 240.77% |
| 2017 Q3 | - CAD | -100.0% |
| 2016 Q2 | 14.45 Thousand CAD | 68.26% |
| 2016 Q3 | - CAD | -100.0% |
| 2016 Q4 | 33.03 Thousand CAD | 0.0% |
| 2016 FY | 56.08 Thousand CAD | -1.08% |
| 2016 Q1 | 8593.00 CAD | 158.14% |
| 2015 Q2 | 30.68 Thousand CAD | 0.0% |
| 2015 Q4 | -14.77 Thousand CAD | -136.23% |
| 2015 Q3 | 40.79 Thousand CAD | 32.92% |
| 2015 FY | 56.69 Thousand CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 13.699% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1.506% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 96.443% |
| GB Sciences, Inc. | -624.00 USD | 66821.795% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 435.083% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 17170.275% |
| Biomind Labs Inc. | -15.42 Thousand USD | 2799.326% |
| ContraFect Corporation | -154 Thousand USD | 370.353% |
| CSL Limited | 7.56 Billion USD | 99.994% |
| CytoDyn Inc. | -29 Thousand USD | 1535.669% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.614% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 962.728% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1319.163% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -135.809% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.65% |
| SQZ Biotechnologies Company | 9.79 Million USD | 95.749% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -569.084% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 97.224% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -533.435% |
| Mesoblast Limited | -35.16 Million USD | 101.184% |
| Marizyme, Inc. | 457.7 Thousand USD | 9.036% |
| Genus plc | 178.7 Million USD | 99.767% |
| Pharming Group N.V. | 220.1 Million USD | 99.811% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 3884.945% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -442.39% |
| IMV Inc. | -962.29 Thousand USD | 143.266% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 207.443% |
| MultiCell Technologies, Inc. | 49.32 USD | -844068.694% |
| ONE Bio Corp. | 20.12 Million USD | 97.931% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 98.966% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 98.526% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 136.471% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -494.777% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 8507.593% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -196.33% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 583.963% |
| Enzolytics Inc. | 30.7 Thousand USD | -1255.816% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.962% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 180.92% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.898% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -13321.792% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 4801.265% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 596.54% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 932.688% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 57.859% |
| EV Biologics, Inc. | 48.9 Thousand USD | -751.419% |
| Q BioMed Inc. | -8988.00 USD | 4732.221% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 95.668% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.061% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 97.301% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 526.954% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 200265.385% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 32.563% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 166.072% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 3617.905% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -135.809% |
| Affymax, Inc. | 1.35 Million USD | 69.322% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 90.965% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -8285.00 USD | 5125.275% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 7.488% |
| SYBLEU INC | 11.69 Thousand USD | -3459.713% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 230.308% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 211.62% |
| Neutra Corp. | 14.33 Thousand USD | -2804.388% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 607.737% |
| PureTech Health plc | -1.6 Million USD | 125.973% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 141.583% |
| IXICO plc | 3.27 Million USD | 87.268% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 159.992% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 123.246% |
| CSL Limited | 7.7 Billion USD | 99.995% |
| Cellectis S.A. | 18 Thousand USD | -2213.022% |